Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Motixafortide · Aphexda, BL-8040

Peptide · Antagonist of C-X-C Motif Chemokine Receptor 4 (CXCR4) · developed by Ayrmid Pharma

Approved FDA, Sep 2023
3 Registered trials

What is Motixafortide?

Motixafortide is a CXCR4 antagonist that blocks binding of stromal-derived factor-1α (CXCL12) to CXCR4, mobilizing hematopoietic stem cells from bone marrow into peripheral circulation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Aphexda, BL-8040, BKT-140
Drug type
Peptide
Targets
C-X-C Motif Chemokine Receptor 4 (CXCR4), C-X-C Motif Chemokine Ligand 12 (CXCL12) (secondary target)
Mechanism
Antagonist of C-X-C Motif Chemokine Receptor 4 (CXCR4)
Pathways
chemotaxis, angiogenesis, hematopoietic stem cell mobilization
Therapy area
Oncology
Developer
Ayrmid Pharma
In trials of
BLRX
FDA status
Approved as Aphexda (September 8, 2023), NDA217159 · FDA label
UNII
DA9G065962

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 4, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03246529 Phase 3 Multiple Myeloma Active not recruiting BLRX
NCT03281369 Phase 1/2 Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Terminated BLRX
NCT06547112 Phase 1 Multiple Myeloma Completed BLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Myeloma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.